United States

United States

Choose language: English

Citations Search

Sort By:

Mol. Cancer Ther. 15, [ePub ahead of print]. Development of a RSK Inhibitor as a Novel Therapy for Triple Negative Breast Cancer 2016

Ludwik, K.A., Campbell, J.P., Li, M., Li, Y., Sandusky, Z.M., Pasic, L., Sowder, M.E., Brenin, D.R., Pietenpol, J.A., O'Doherty, G.A. and Lannigan, D.A.

Notes: 2D and 3D proliferation assays were performed using the CellTiter-Glo® Reagent with a GloMax® Discover System. (4745)

Expand Full Notes »

Oncotarget 7, 8172-8183. Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling 2016

Hsu, C.W., Huang, R., Khuc, T., Shou, D., Bullock, J., Grooby, S., Griffin, S., Zou, C., Little, A., Astley, H. and Xia, M.

Notes: The rAAV-mediated genome editing technology was used to introduce a NanoLuc® reporter sequence downstream of and in frame with the last coding exon of the HIF1A gene in HCT116 cells. This created a reporter cell line with a single allele of HIF1A endogenously tagged with a NanoLuc® reporter fusion. The cell line was used to study compound inhibition of Hif1a signaling. NanoLuc® luciferase activity was measured using Nano-Glo® reagent. For qHTS, cells at 1500 cells/well in 1536-well plates were incubated with test compounds at 37°C, 5% CO2, 1% O2 for 18 hours in a humidified CO2 incubator with variable oxygen control, followed by addition of Nano-Glo® reagent or CellTiter-Glo® cell viability assay reagent. The HRE-bla assay was conducted using the CellTiter-Glo® reagent. HCT116 and ME-180 cell proliferation was quantified as relative luminescence unit (RLU) values using the CellTiter-Glo® viability assay reagent. (4761)

Expand Full Notes »

J. Lab. Autom. 21, 27–36. Precision cancer medicine in the acoustic dispensing Era: Ex vivo primary cell drug sensitivity testing. 2016

Kulesskiy, E., Saarela, J., Turunen, L. and Wennerberg, K.

Notes: The authors used the CellTiter-Glo® Cell Viability Assay and CellTox™ Green Cytotoxicity Assay to monitor the reproducibility of their acoustic dispensing. The authors report that adding CellTox™ Green Cytotoxicity Assay at plating "gives more solid signals than adding at the end of the assay” and speculate that the dye stabilizes the DNA of dead cells. The CellTiter-Glo® Assay data supports that the dye is nontoxic in the 72-hour incubation. The authors routinely predispense 12.5nl of CellTox™ Green with preplated compounds into 1536-well assay plates using an Echo 550 device and store plates under nitrogen gas in storage pods to produce assay-ready plates awaiting cell additions. The authors also report preliminary results of using the nonlytic RealTime-Glo® Viability Assay and find highly correlated results with the lytic CellTiter-Glo® Assay. The authors relate that use of the nonlytic RealTime-Glo® and CellTox™ Green Assays open the possibility of doing further work with the same cells. (4703)

Expand Full Notes »

Nat. Med. 22, 262–9. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. 2016

Hata, A.N., Niederst, M.J., Archibald, H.L., Gomez-Caraballo, M., Siddiqui, F.M., Mulvey, H.E., Maruvka, Y.E., Ji, F., Bhang, H.C., Radhakrishna, V.K., Siravegna, G., Hu, H., Raoof, S., Lockeerman, E., Kalsy, A., Lee, D., Keating, C.I., Ruddy, D.A., Damon, L.J., Crystal, A.S., Costa, C., Piotrowska, Z., Bardelli, A., Iafrate, A.J., Sadreyev, R.I., Stegmeier, F., Getz, G., Sequist, L.V., Faber, A.C. and Engelman, J.A.

Notes: This study investigated the reason why cancers become resistant to anti-cancer treatments over time. Non-small-cell lung cancers were cultured for weeks in the presence of EGF receptor inhibitors and resistant clones obtained based on a specific mutation in the EGF receptor. Clones that became resistant within 6 weeks were found to result from cells already containing the EGFR mutation. Clones taking about 24 weeks to become resistant evolved from the EGFR mutation. RealTime-Glo™ MT Cell Viability Assay was employed in several studies over a 10-week period to monitor proliferation (data presented in Supplementary Figures). Each week prior to media change, RealTime-Glo™ Assay reagents were added, incubated for 1 hour and luminescence measured. After 72-hour incubations, short-term viability was measured with the CellTiter-Glo® Luminescent Cell Viability Assay. (4699)

Expand Full Notes »

Cell Death Differ. 23, 1873–85. FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration.  2016

Yu, C., Kim, B.S. and Kim, E. 

Notes: Mouse embryonic fibroblasts were treated with vehicle or DPQ for 1 hour followed by exposure to H2O2.  Intracellular NAD+ was measured with the NAD/NADH-Glo™ Assay and cellular ATP was measured with the CellTiter-Glo® Viability Assay. (4845)

Expand Full Notes »

J. Med. Chem. 58, 2718–36. 9H-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain. 2015

Picaud, S., Strocchia, M., Terracciano, S., Lauro, G., Mendez, J., Daniels, D.L., Riccio, R., Bifulco, G., Bruno, I. and Filippakopoulos, P.

Notes: The authors used bioluminescence resonance energy transfer (BRET) to test the ability of a bromodomain 9 ligand to disrupt binding to histone. HEK 293 cells were cotransfected with a histone H3.3-HaloTag® fusion vector and either NanoLuc®-BRD9 bromodomain or NanoLuc®-full-length BRD4 fusion vector. After 24 hours, the transfected cells were trypsinized, diluted in phenol red-free DMEM with or without 10nM of HaloTag® NanoBRET™ 618 Ligand and dispensed into a 96-well plate. One of two potential BRD-disrupting compounds, 7d or 11, was adding to a final concentration of 0.005–33μM, cells were incubated for 18 hours and NanoBRET™ Nano-Glo® Substrate (final concentration 10µM) was added. Fluorescence was measured and a corrected BRET ratio calculated. Cytotoxicity was assessed after the NanoBRET™ assay by incubating the cells with the CellTiter-Glo® Reagent for 30 minutes and measuring luminescence. To examine histone H3.3 localization, HEK 293 cells were transfected with the histone H3.3-HaloTag® fusion vector using FuGENE® HD Transfection Reagent. After 24 hours, cells were labeled with 5μM HaloTag® TMR ligand for 15 minutes before washing with complete medium, incubated for 30 minutes and imaged with a confocal microscope. (4568)

Expand Full Notes »

Assay Drug Dev. Technol. 13, 456–65. Bioluminescent, nonlytic, real-time cell viability assay and use in inhibitor screening 2015

Duellman, S.J., Zhou, W., Meisenheimer, P., Vidugiris, G., Cali, J., Gautam, P., Wennerberg, K. and Vidugiriene, J.

Notes: The authors describe a homogeneous, nonlytic, bioluminescent assay that measures cell viability in real time. They monitored cell health for 72 hours from the same test samples, distinguished differential cell growth, and investigated drug mechanism of action by analyzing time- and dose-dependent drug effects. The real-time measurements enabled them to detect cell death immediately (>75% signal decrease within 15 minutes of digitonin addition), analyze drug potency versus efficacy, and identify cytostatic versus toxic drug effects.They then screened an oncology compound library (Z′ = 0.7) and identified compounds with varying activity at different time points. (4590)

Expand Full Notes »

Mol. Cell. Biol. 35, 1805–24. Molecular mechanism for the control of eukaryotic elongation factor 2 kinase by pH: Role in cancer cell survival. 2015

Xie, J., Mikolajek, H., Pigott, C.R., Hooper, K.J., Mellows, T., Moore, C.E., Mohammed, H., Werner, J.M., Thomas, G.J. and Proud, C.G.

Notes: A549 and HCT116 cells were transfected with an inducible shRNA to reduce eEF2K levels. Culturing of the cells at various medium pH lead to a decrease in viability and increase in cytotoxicity, which was increased when the shRNA was induced. Cell viability was measured with the CellTiter-Glo® Luminescent Cell Viability Assay, and cytotoxicity was measured with the CellTox™ Green Cytotoxicity Assay. (4712)

Expand Full Notes »

Biomaterials 56, 140–153. Ruthenium(II) polypyridyl complexes as mitochondria-targeted two-photon photodynamic anticancer agents 2015

Liu, J., Chen, Y., Li, G., Zhang, P., Jin, C., Zeng, L., Ji, L. and Chao, H.

Notes: The authors of this study use large 3D multipcellular spheroids (MCSs, >200µm) to serve as intermediate models between 2D cell culture and in vitro systems for investigating drug delivery and photodynamic therapy (PDT) for cancer. They evaluate four metal complexes that target the mitocondrion for PDT in 3D MCSc formed from HeLa cells. Cell viability is evaluated in the standard 2D culture system using the CellTiter-Glo® Cell Viability Assay, and in the 3D MCS using the CellTiter-Glo® 3D Cell Viability Assay. (4583)

Expand Full Notes »

Nat. Commun. 6, 8089. Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds 2015

Delfosse, V., Dendele, B., Huet, T., Grimaldi, M.,  Boulahtouf, A., Gerbal-Chaloin, S., Beucher, B., Roecklin, D., Muller, C., Rahmani, R., Cavaillès, V., Daujat-Chavanieu, M., Vivat, V., Pascussi, J-M., Balaguer, P. and Bourguet, W.

Notes: Humans are exposed to a cocktail of low-dose chemicals in the environment, through diet, and through medication. However, most studies looking at compound toxicity, look at these compounds in isolation, not as they might be encountered in the environment—in mixtures. The pregnane X receptor (PXR) is a xenoreceptor that has been identified by the US Environmental Protection Agency as a major target of environmental and dietary chemicals, and many studies have highlighted the role of nuclear receptors like PXR in transducing the deleterious effects of endocrine disrupting compounds in the environment. The authors of this study used compound screening and functional analysis to demonstrate that the combined use of an environmentally persistent organochlorine pesticide and the active component of contraceptive pills (17α-ethinylestradiol) produces synergistic effects on PXR and expression of its target gene, the cytochrome P450 gene, CYP34A. Gene expression of CYP3A4 was measured using a luciferase reporter created in a pGL3-basic backbone. Activity of the CYP3A4 protein was measured in primary human hepatocytes using the P450-Glo™ CYP3A4 Assay with Luciferin-IPA, and cell number was normalized using the CellTiter-Glo® Luminescent Cell Viability Assay. (4579)

Expand Full Notes »

Proc. Natl. Acad. Sci. USA 111, 2349–54. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. 2014

Mathews Griner, L.A., Guha. R., Shinn. P., Young, R.M., Keller,J.M., Liu, D., Goldlust, I.S., Yasgar, A., McKnight, C., Boxer, M.B., Duveau, D.Y., Jiang, J.K., Michael, S., Mierzwa, T., Huang, W., Walsh, M.J., Mott, B.T., Patel, P., Leister, W., Maloney, D.J., Leclair, C.A., Rai, G., Jadhav, A., Peyser, B.D., Austin, C.P., Martin, S.E., Simeonov, A., Ferrer, M., Staudt, L.M. and Thomas, C.J.

Notes: To avoid the trial-and-error methodology involved in developing multidrug treatments, the authors designed and tested a platform for high-throughput combination screening to easily discover pairs of small molecules that could then be explored further. Cell lines tested were dispensed at 1,000 cells per well in 5µl of medium into a 1,536-well plate either directly to compound matrix plates or adding 23nl of bortezomib and library compounds to the cells. After a 48-hour incubation, 3µl of CellTiter-Glo® Luminescent Cell Viability Assay reagent was dispensed and luminescence read to assess cell proliferation. (4209)

Expand Full Notes »

Bioorg. Med. Chem. Lett. 23, 4398–403. Identification of potent Yes1 kinase inhibitors using a library screening approach. 2013

Patel, P.R., Sun, H., Li, S.Q., Shen, M., Khan, J., Thomas, C.J. and Davis, M.I.

Notes: This article describes how a miniaturized high-throughput biochemical assay for Yes1 kinase was developed and used for screening inhibitors in small molecule libraries. Kinase activity of Yes1 was assessed by dispensing 2µl of Yes1 enzyme in a 1,536-well white multiwell plate and mixing with compounds and substrate for a total kinase reaction volume of 25µl. The amount of ADP was quantitated using the ADP-Glo™ Kinase Assay and normalized to vehicle and minus-enzyme controls. Some of the inhibitors identified in the in vitro assay were tested in a cell-based assay. Two rhabdomyosarcoma cell lines, RD and RH30, were seeded at 4,000 cells/well in a 96-well plate with 100µl of culture medium. After an overnight incubation, 100µl of medium with 0, 0.1, 1, 5, 10, 15 or 20μM of inhibitor (final concentration) was added. After 48 hours, the number of cells was assessed using the CellTiter-Glo® Luminescent Cell Viability Assay. (4354)

Expand Full Notes »

J. Biomol. Scr. 17, 993–8. Development of a novel ectonucleotidase assay suitable for high-throughput screening. 2012

Sachsenmeier, K.F., Hay, C., Brand, E., Clarke, L., Rosenthal, K., Guillard, S., Rust, S., Minter, R. and Hollingsworth, R.

Notes: The authors of this paper describe the development of a high-throughput assay to screen for antibody inhibitors of 5´-ectonucleotidase activity (converts AMP to adeonsine plus free phosphate). They used the CellTiter-Glo® Cell Viability Assay to screen for activity. The CellTiter-Glo® luciferase reaction is inhibited by AMP; activity of 5´-ectonucleotidase eliminates AMP, thereby relieving the reaction from inhibition, producing light. The authors demonstrate release of the luciferase reaction from inhibition as a result of 5´-ectonucleotidase activity, and that they were able to show inhibition of 5´-ectonucleotidase activity by anti-5´-ectonucleotidase antibodies. (4261)

Expand Full Notes »

J. Animal Sci. epub . Direct fed microbial supplementation repartitions host energy to the immune system 2012

Qiu, R., Croom, J., Ali, R.A., Ballou, A.L., Smith, C., Ashwell, C.M., Hassan, H.M., Chiang, C.-C. and Koci, M.D.

Notes: The authors of this study investigated the energetic effects of direct fed microbials on 1-day-old broiler chicks. They looked at body weight, feed consumption, whole-body energy expenditure, organ mass, tissue respiration rates and peripheral blood mononuclear cell (PBMC) ATP levels to explore effects on energy metabolism in control-diet chicks versus chicks receiving direct fed microbials. An ATP assay was used because previous attempts to monitor O2 use by PMBCs were inconclusive. PBMC ATP levels were measured using the CellTiter-Glo™ Luminescent Cell Viability Assay in 96-well plates using 10 × 105 cells/well. The authors also looked for differences in ATP depletion in control and experimental chick populations by using an ATP synthase inhibitor and a proton ionophore. In this study, the authors concluded that the PMBC isolated from the direct microbial fed animals consumed more ATP/cell than the controls. (4202)

Expand Full Notes »

J. Biomol. Scr. 16(9), 995–1006. A biochemical screen for identification of small-molecule regulators of the wnt pathway using Xenopus egg extracts. 2011

Thorne, C.A., Lafleur, B., Lewis, M., Hanson, A.J., Jernigan, K.K., Weaver, D.C., Huppert, K.A., Chen, T.W., Wichaidit, C., Cselenyi, C.S., Tahinci, E., Meyers, K.C., Waskow, E., Orton, D., Salic, A., Lee, L.A., Robbins, D.J., Huppert, S.S. and Lee, E.

Notes: The authors used a biochemical assay using Xenopus egg extracts to monitor degradation levels of two Wnt pathway components, Axin and ß-catenin, and identify modulators of the Wnt pathway. ß-catenin and Axin were expressed in vitro as firefly and Renilla luciferase fusion proteins, respectively, using the TNT® SP6 High-Yield Protein Expression System and shown to behave in Xenopus extracts in a similar way to wildtype proteins, which were expressed as radiolabled proteins in rabbit reticulocyte lysate. Degradation of labeled proteins was monitored by SDS polyacrylamide gel electrophoresis and autoradiography, and degradation of luciferase fusion proteins was examined using the Dual-Glo® Luciferase Assay. Using the Xenopus extract-based assay, the authors screened chemical libraries to identify two modulators of the Wnt pathway, then confirmed this inhibition in HEK 293 cells by demonstrating a decrease in ß-catenin expression with increasing concentrations of the inhibitors. This decrease in ß-catenin-Fluc levels was measured using the Steady-Glo™ Luciferase Assay, and luciferase activity was normalized to cell viability, as determined using the CellTiter-Glo® Assay. (4181)

Expand Full Notes »

Assay Drug Dev. Technol. , epub ahead of print. Assessment of Compound Hepatotoxicity Using Human Plateable Cryopreserved Hepatocytes in a 1,536-well-plate Format. 2011

Moeller, T.A., Shukla, S.J. and Xia, M.

Notes: Here the authors describe development of an HTS cell viability assay protocol for use with cultured cyropreserved human primary hepatocytes. Cryopreserved hepatocytes for culturing were prepared as suspensions and dispensed at 2,000 or 4,000 cells/5µl/well in collagen I-coated 1,536-well plates. Cells were allowed to attach and then 23nl of each test compound was added in a dilution series from 2.8nM to 92µM, and cells incubated for 24 or 40 hours. Five microliters of CellTiter-Glo® Reagent was added and cells were incubated 30 minutes before reading the luminescent output. IC50 values for 12 compounds were determined; a summary of the protocol is provided in Table 1 of the paper. Cultured cryopreserved hepatocytes were assayed for function using the P450-Glo® CYP3A4 assay with the Luciferin-IPA substrate. (4182)

Expand Full Notes »

Clin. Can. Res. 17(15), 5071-81. HER2-affitoxin: A potent therapeutic agent for the treatment of HER2-overexpressing tumors. 2011

Zielinski, R., Lyakhov, I., Hassan, M., Kuban, M., Shafer-Weaver, K., Gandjbakhche, A. and Capala, J.

Notes: The authors used the CellTiter®-Glo Assay to assess the effect of HER2-Affitoxin on cell viability of gastric carcinoma NCI-N87 cells, which overexpress HER2. The HER2-Affitoxin is a fusion protein of a HER2-specific Affibody and modified Pseudomonas aeruginosa exotoxin A (PE 38). This fusion protein was designed to offer an alternative method for treating tumors that do not respond to trastuzumab or have acquired resistance to current therapies. The CellTiter-Glo® Assay was used to calculate HER2-Affitoxin IC50 values of cells in culture. They describe the mechanism of action as follows: HER2-Affitoxin binds to HER2 protein on the cell surface, is internalized, where it blocks protein synthesis in the cytosol via ADP ribosylation of eEF-2. (4131)

Expand Full Notes »

J. Biol. Chem. 286, 21546–21554. TWEAK induces apoptosis through a death-signaling complex comprising Receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. 2011

Ikner, A. and Ashkenazi, A.

Notes: The authors of this study set out to describe the mechanism of cell death through which TNF-like weak inducer of apoptosis (TWEAK) exerts its apoptotic effect on certain cancer cells. The used the CellTiter-Glo® Cell Viability Assay and the Caspase-Glo® 3/7 Assay to investigate cell viability and mechanism of cell death in HSC3 cells treated with TWEAK. They looked at caspase-8 activity in cells treated with TWEAK in the presence or absence of a caspase-8 inhibitor using the Caspase-Glo® 8 Assay. They showed that TWEAK induces caspase-dependent apoptosis in these cells. (4170)

Expand Full Notes »

Biochem. Pharmacol. epub ahead of print. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action 2010

Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP, Xia M.

Notes: Dysregulation of the NF-kB pathway has been associated with the formation of a wide variety of tumors and other cancers, as well as diseases, including chronic inflammation and immunodeficiency. Because of the association of constitutive NF-kB regulation and tumors, inhibition of the NF-kB pathway by small molecule antagonists was thought to be a means of reversing or halting the growth and spread of tumors. The authors screened compounds from a database (the NCGC Pharmaceutical Collection or NPC) of small molecule compounds: 52% of the compounds have been approved for human or animal use by the FDA, 22% were drugs approved for use in Europe, and another 25% either drugs approved in other countries or compounds that have been tested in clinical trials. The database served as a source from which to rapidly and efficiently identify already approved drugs that inhibited NF-kB. They used a quantitative high-throughput screening format. To identify small molecules that could inhibit the NF-kB pathway, the compounds were initially screened using a cell-based NF-kB lactamase reporter gene assay, with TNFalpha and MG132 as positive controls. (TNFalpha induced NF-kB coupled beta-lactamase activity, while MG132 blocked TNFalpha induction NF-kB-coupled beta-lactamase activity.) After several rounds of screening, 20 compounds were further studied for their NF-kB inhibition, with NF-kB luc2P HEK293 cells. After a concordance rate of 95% between the luciferase and beta-lactamase tests, compounds were additionally examined for their ability to affect caspase 3/7 activity, for the ability to disrupt the electrochemical gradient across the mitochondrial membrane in relation to cellular apoptosis, as well as tests of the inhibitors on cancer cell viability and affects on LDH release, an indicator of cell necrosis.

Expand Full Notes »

J. Lipid Res. 51, 2211–2222. Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells. 2010

Zhang, L.H., Kamanna, V.S., Ganji, S.H., Xiong, X-M. and Kashyap, M.L.

Notes: The authors investigated the role of pioglitazone on transcriptional regulation of the apoA-I gene and looked at the biological properties of pioglitazone-induced apoA-I-containing high-density lipoprotein particles (HDL). To investigate the biological properties of the HDL particles, the authors treated THP-1 cells with conditioned medium from HepG2 cultures treated or untreated with pioglitazone and looked at adhesion to human aortic endothelial cells (HAEC). During the experiment, HAEC viability and proliferation were monitored using the CellTiter-Glo® Luminescent Cell Viability Assay. Additionally, to determine whether pioglitazone stimulates apoA-I transcription, a luciferase reporter construct was made containing the apoA-I gene promoter. Transfected cells were treated with pioglitazone, and luciferase expression was monitored using the Dual-Luciferase® Reporter Assay System. (4173)

Expand Full Notes »

Cell 138, 645-59. Identification of selective inhibitors of cancer stem cells by high-throughput screening. 2009

Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A. and Lander, E.S.

Notes: The authors of this study describe a proof-of-concept screen to use mammary epithelial cells that have been induced to undergo an epithelial to mesenchymal transition (EMT) as model cells to identify agents that may be selectively toxic against "epithelial cancer stem cells" (CSCs). They induced the transformed breast cancer cell line HMLER to undergo a mesenchymal transition using shRNA directed against the E-cadherin gene. They characterized the responsiveness of these transitioned cells to common cytotoxic agents using the CellTiter® 96 AQueous Cytotoxicity Assay and compared the response to that of HMLER cells containing a control shRNA. They showed that the HMLER cells induced to undergo EMT behaved more like CSCs. The researchers then performed a proof-of-concept high-throughput screen to identify compounds that targeted the HMLER cells induced to undergo EMT, using the CellTiter-Glo® Assay to assess cell viability. (4006)

Expand Full Notes »

Current Chemical Genomics 3, 33-41. In vitro viability and cytotoxicity testing and same-well multi-parametric combinations for high-throughput screening 2009

Niles, A.L., Moravec, R.A. and Riss, T.L.

Notes: The authors review the use of in vitro cytotoxicity testing in drug discovery to characterize the toxic potential of new chemical entities (nce) at the earliest stages of profiling. DOI: 10.2174/1875397300903010033 (4000)

Expand Full Notes »

Toxicology in Vitro 23, 1170-1171. Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds 2009

Wu, Y., Connors, D., Barber, L., Jayachandra, S., Hanumegowda, U.M. and Adams, S.P.

Notes: The authors describe a multiplexed in vitro assay to detect nephrotoxicity and gain information about mechanism of cell death in HK-2 (human kidney-2) cells. The multiplexed assay involved an LDH assay to detect necrosis, a caspase-3/7 assay to detect apoptosis, a reazurin assay to assess metabolic state, and a DNA dye staining assay to monitor nuclear morphology. (4002)

Expand Full Notes »

Cancer Res. 69, 896–904. Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1. 2009

Zheng, Y., Ritzenthaler, J.D., Sun, X., Roman, J. and Han, S.

Notes: In this paper, the role of prostaglandin E2 (PGE2) stimulation of integrin-linked kinase (ILK) in human lung carcinoma was explored. Mutations of Sp1 and NF-κB cis-acting elements in an ILK promoter-pGL3-Basic Vector construct were created using the GeneEditor™ in vitro Site-Directed Mutagenesis System. The mutations were confirmed via sequencing. Human non–small cell lung carcinoma (NSCLC) cells were plated at a density of 5 × 105 cells per well in six-well plates and transfected with 2µg of ILK promoter reporter vectors with or without 0.2µg of the phRL-TK Renilla Luciferase Reporter Vector. After 24 hours, the transfected cells were exposed to PGE2 and the cells lysed for assessment using the Dual-Luciferase® Reporter Assay System. NSCLC cells were transfected with inactive (ILK-S343A) and superactive ILK (ILK-S343D) cDNA, incubated for 24 hours, treated with or without exogenous PGE2 or with an Sp1 inhibitor for 2 hours. The numbers of viable cells were measured using the CellTiter-Glo® Luminescent Cell Viability Assay. (4026)

Expand Full Notes »

Expert Opin. Drug Metab. Toxicol. 4, 103–120. Bioluminescent assays for ADMET 2008

Cali, J.J., Niles, A., Valley, M.P., O’Brien, M.A., Riss, T.L., and Shultz, J.

Notes: The authors of this review article highlight the use of bioluminescence as a readout for high-throughput ADME/Tox assays. They discuss three strategies for designing bioluminescent assays, using either luciferase, ATP or luciferin substrates as the limiting reagents for a luciferase-catalyzed reaction. Reporter gene assays limit the production of luciferase by tying it to a promoter or DNA regulatory region of interest. Such assays can be used to study genes that are regulated by drugs and other xenobiotics. Bioluminescent assays in which ATP is the limiting reagent of the luciferase reaction can be designed to monitor cell viability or the activity kinases. Bioluminescent assays in which the substrate is limiting can be designed so that the activity of a particular enzyme results in the production of a luciferin substrate that can, in turn, be acted upon by luciferase. (3926)

Expand Full Notes »

Choose your country


United States

Pacific Asia

Korea, Republic of


United Kingdom